TRVI
HEALTHCARETrevi Therapeutics Inc
AI Insight
What's Moving TRVI Today?
No stock-specific AI insight has been generated for TRVI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.41$18.11
$17.38
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-33.6%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding142.0M
TRVI News
22 articles- Trevi Therapeutics Announces Upcoming June and July Event ScheduleYahoo Finance·Jun 17, 2026
- Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.Motley Fool·Jun 3, 2026
- F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVIMarketBeat·May 10, 2026
- Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVIMarketBeat·May 10, 2026
- Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030Marketbeat·May 9, 2026
- Trevi Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030Yahoo Finance·May 6, 2026
- Trevi Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 5, 2026
- Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·Apr 30, 2026
- Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026Yahoo Finance·Apr 28, 2026
- Trevi Therapeutics to Participate in Upcoming May EventsYahoo Finance·Apr 23, 2026
- Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?Yahoo Finance·Apr 22, 2026
- Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesYahoo Finance·Apr 20, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate EarningsYahoo Finance·Apr 17, 2026
- Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockBenzinga·Apr 17, 2026
- Trevi Therapeutics Announces Proposed Public Offering of Common StockYahoo Finance·Apr 16, 2026
- A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic CoughYahoo Finance·Apr 5, 2026
- Trevi Therapeutics to Participate in Upcoming EventsYahoo Finance·Apr 1, 2026
- As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?Motley Fool·Mar 23, 2026
- Trevi Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Trevi Therapeutics (TRVI) Earnings TranscriptMotley Fool·Mar 18, 2026
All 22 articles loaded
Price Data
Open$17.49
Previous Close$17.71
Day High$18.16
Day Low$17.34
52 Week High$18.11
52 Week Low$5.41
52-Week Range
$5.41$18.11
$17.38
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-33.6%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding142.0M
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—